Sales Force Support 2007

November 2007
November 2007
Although barely a year has passed since Pfizer ushered in the era of the downsized sales operation with the announcement that it would cut its reps by 20%, already the strategy back then of striving to be the biggest seems strangely outdated. But while the market for extra bodies in the field may be waning, there are plenty of other services in hot demand by pharmaceutical sales forces.

Doing more with less means increasing efficiency and that can demand  better research, analysis, planning and segmentation, or the implementation of the latest interactive detailing technology.  That's not to say there is no longer a demand for call centers, sample management and fulfillment, sales rep training and contact management systems…

On the following pages is a directory of firms offering a variety of sales support planning and analytics services—from conventional call centers and contract sales forces to state-of-the-art tracking software and innovative rep training programs.

For further information on these companies and products, please refer to the 2007 Pharmaceutical Marketers Directory, from which most of the information in this section was derived.

Details of how to obtain a copy of the PMD can be found on page 4 of this issue (below the “Contributors” section). For listings information and opportunities, call Suzanne Besse at (561) 237-6122 or email
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.